Epilepsy is a chronic neurological disorder that affects millions of people worldwide. The diagnosis and management of epilepsy can be challenging, and there is a need for reliable biomarkers to aid in early diagnosis and monitoring disease progression.
Neurological biomarkers for epilepsy include measures of gamma-aminobutyric acid, glutamate, and cytokine levels in blood or cerebrospinal fluid, as well as brain imaging techniques such as MRI and electroencephalography. These biomarkers have shown promise in identifying the severity of epilepsy, predicting outcomes, and monitoring treatment response.
The use of neurological biomarkers in the diagnosis and treatment of epilepsy holds great promise for improving outcomes for epilepsy patients. Future research should focus on the validation of these biomarkers in larger cohorts and their integration into clinical practice to improve early diagnosis and treatment of epilepsy.
Muotri's lab, temporarily, has seen that cytokines--proteins generated by cells in the body--are a strong link between infection and neurotoxicity. They are currently reviewing whether raised cytokines, such as IL-6, may be a neurological biomarker of autism and schizophrenia, problems associated to chronic infection that is thought to be neurotoxic. These survey shows the method neuroscience scientists are buying neurological biomarker science that can assist patient care and quicken the growth of effective therapeutics for neurological disorder. They also show numerous fields that might be ripe for expenditure and should be further used by physicians, scientists, and biopharmaceutical organization.
Read More:
http://thrivearticles.weebly.com/article/neurological-biomarkers-are-found-in-cerebral-spinal-fluid
